A5020480277- Coronary Interventions and Diagnostics
- Acute Myocardial Infarction Research
- Cardiac Imaging and Diagnostics
- Cardiac Valve Diseases and Treatments
- Antiplatelet Therapy and Cardiovascular Diseases
- Vascular Procedures and Complications
- Cerebrovascular and Carotid Artery Diseases
- Lipoproteins and Cardiovascular Health
- Venous Thromboembolism Diagnosis and Management
- Central Venous Catheters and Hemodialysis
- Cardiac, Anesthesia and Surgical Outcomes
- Cardiac Structural Anomalies and Repair
- Peripheral Artery Disease Management
- Heart Failure Treatment and Management
- Cardiac Health and Mental Health
- Advanced MRI Techniques and Applications
- Aortic aneurysm repair treatments
- Blood Pressure and Hypertension Studies
- Atrial Fibrillation Management and Outcomes
- Cardiac Arrhythmias and Treatments
- Cardiovascular Issues in Pregnancy
- Organ Transplantation Techniques and Outcomes
- Cardiac tumors and thrombi
- Integrated Circuits and Semiconductor Failure Analysis
- Cardiovascular Function and Risk Factors
Hôpital Beau-Séjour
2023-2025
University Hospital of Geneva
2018-2025
University of Lausanne
2009-2023
Radiance Technologies (United States)
2023
Geneva College
2020
Hammersmith Hospital
2018
Imperial College London
2018
University Hospital of Lausanne
2009-2017
Hôpital Orthopédique de la Suisse Romande
2012
Hospital Materno-Infantil
1996-2003
Coronary plaques that are prone to rupture and cause adverse cardiac events characterized by large plaque burden, lipid content, thin fibrous caps. Statins can halt the progression of coronary atherosclerosis; however, effect proprotein convertase subtilisin kexin type 9 inhibitor alirocumab added statin therapy on burden composition remains largely unknown.To determine effects atherosclerosis using serial multimodality intracoronary imaging in patients with acute myocardial infarction.The...
Currently, transradial access (TRA) is the recommended for coronary procedures because of increased safety, with radial artery occlusion (RAO) being its most frequent complication, which will increasingly affect patients undergoing multiple during their lifetimes. Recently, distal (DRA) has emerged as a promising alternative to minimize RAO risk. A large-scale, international, randomized trial comparing TRA and DRA lacking. The aim this study was assess superiority compared conventional...
In this study, a systematic analysis was conducted of phasic intracoronary pressure and flow velocity in patients with severe aortic stenosis (AS) coronary artery disease, undergoing transcatheter valve replacement (TAVR), to determine how AS affects: 1) flow; 2) hyperemic 3) the most common clinically used indices severity, instantaneous wave-free ratio fractional reserve. A significant proportion have concomitant disease. The effect on pressure, flow, established invasive clinical severity...
To determine whether treatment and outcomes of older acute coronary syndrome (ACS) patients changed over time.We analysed the use guideline-recommended therapies in-hospital 13 662 ACS ≥70 years enrolled in prospective Acute Myocardial Infarction Switzerland (AMIS) cohort between 2001 2012 according to 4-year periods (2001-2004, 2005-2008, 2009-2012). Between first last period, percutaneous intervention (PCI) increased from 43.8 69.6% ( ITALIC! P < 0.001). Use drugs as well increased. At...
A third-generation coronary drug-eluting resorbable magnesium scaffold (DREAMS 3G) was developed to enhance the performance of previous generations and achieve angiographic outcomes comparable those contemporary stents.This prospective, multicenter, non-randomized, first-in-human study conducted at 14 centers in Europe. Eligible patients had stable or unstable angina, documented silent ischemia, non-ST-elevation myocardial infarction, a maximum two single de novo lesions separate arteries...
The third-generation coronary sirolimus-eluting magnesium scaffold, DREAMS 3G, is a further development of the 2G (commercial name Magmaris), aiming to provide performance outcomes similar drug-eluting stents (DES).
To assess the feasibility and safety of 7 French (Fr) Glidesheath Slender for complex transradial (TR) percutaneous coronary interventions (PCI).The TR approach is increasingly used worldwide peripheral vascular interventions. However, small size radial artery remains an important limitation use large-bore guiding catheters (>6 Fr), restricting thereby treatment highly lesions through approach. The Fr slender (Terumo, Tokyo, Japan) a new dedicated sheath with thinner wall hydrophilic...
The aim of this study was to investigate the safety and efficacy biodegradable-polymer sirolimus-eluting stents (BP-SES) compared with durable-polymer everolimus-eluting (DP-EES) in patients ST-segment elevation myocardial infarction (STEMI). Primary percutaneous coronary intervention (PCI) is an effective treatment for STEMI, long-term outcomes are determined by profile newest generation drug-eluting stents. BIOSTEMI (A Comparison Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting...
During transradial (TR) access, it remains unclear whether differences in baseline patients characteristics and hemostasis care impact the rate of radial artery occlusion (RAO). We sought to compare RAO after TR access with 6 French(Fr) Glidesheath Slender (GSS6Fr, Terumo, Japan) or a standard 5 Fr sheath Japanese non-Japanese patients.The Radial Artery Patency Bleeding, Efficacy, Adverse evenT (RAP BEAT) trial randomized 1,836 undergoing coronary angiography and/or interventions receive...
AIM To assess the impact of first wave COVID-19 pandemic on acute coronary syndromes and delay from symptom onset to medical contact among patients presenting with ST-segment elevation myocardial infarction (STEMI), as well investigate whether there were patient-related reasons related for delaying contact. METHODS AND RESULTS All undergoing percutaneous intervention (PCI) at Geneva University Hospitals (ACS) during compared a control group consisting all ACS who underwent PCI same period in...
The hepatic response after ST-elevation myocardial infarction (STEMI) may be associated with mortality and morbidity. We aimed to assess the cardio-hepatic axis post-STEMI using cardiovascular magnetic resonance (CMR).
Physicians are not always comfortable deferring treatment of a stenosis in the left anterior descending (LAD) artery because perception that there is high risk major adverse cardiac events (MACE). The authors describe, using DEFINE-FLAIR (Functional Lesion Assessment Intermediate Stenosis to Guide Revascularisation) trial, MACE rates when LAD lesions deferred, guided by physiological assessment fractional flow reserve (FFR) or instantaneous wave-free ratio (iFR).